The European Medicines Agency (EMA) approved Ryzneuta to reduce neutropenia and febrile neutropenia during chemotherapy. It works by increasing the production and differentiation of mature neutrophils. Niapelf, a generic of Xeplion, was approved for the maintenance treatment of schizophrenia in adults. The EMA refused the marketing authorization for Nezglyal, a treatment for cerebral adrenoleukodystrophy, due to concerns about its efficacy and safety. A similar refusal was made for Syfovre, a treatment for age-related macular degeneration. Additionally, the EMA endorsed recommendations to minimize risks for medicines containing pseudoephedrine, due to rare adverse effects like posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome.
Source link
Europe Approves Neutropenia and Schizophrenia Treatments
